 Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11, 2023 LOS ANGELES, CA, Dec. 28, 2022 GLOBE NEWSWIRE Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. Nasdaq: IMMX ImmixBio, Company, We or Us today announced that updated NXC-201 clinical data has ... The post Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Bloo... 